U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H38N2O
Molecular Weight 454.6462
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EZLOPITANT

SMILES

COC1=CC=C(C=C1CN[C@H]2C3CCN(CC3)[C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C(C)C

InChI

InChIKey=XPNMCDYOYIKVGB-CONSDPRKSA-N
InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1

HIDE SMILES / InChI
Molecular Formula C31H38N2O
Molecular Weight 454.6462
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Ezlopitant (CJ-11974) is a non-peptide neurokinin-1 receptor antagonist. Pfizer was developing ezlopitant for the potential treatment of irritable bowel syndrome and chemotherapy-induced emesis. Development of ezlopitant has been discontinued.

CNS Activity

CNS Active
4002
Curator's Comment: Ezlopitant is CNS active in animals. No human data available.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
Patents

Patents

20010036943
6

Sample Use Guides

In Vivo Use Guide
Randomized phase II study of ezlopitant (CJ-11974) in the control of cisplatin-induced emesis. Patients were randomly assigned to two groups: group 1 received CJ-11,974 100 mg, and group 2 received placebo orally 30 minutes before and 12 hours after cisplatin and then twice daily on days 2 through 5 after cisplatin.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:40:51 GMT 2025
Edited
by admin
on Mon Mar 31 19:40:51 GMT 2025
Record UNII
3L098A8MPY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EZLOPITANT
INN   USAN  
INN   USAN  
Official Name English
ezlopitant [INN]
Preferred Name English
CJ-11,974
Code English
1-Azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-, (2S,3S)-
Systematic Name English
1-AZABICYCLO(2.2.2)OCTAN-3-AMINE, 2-(DIPHENYLMETHYL)-N-((2-METHOXY-5-(1-METHYLETHYL)PHENYL)METHYL)-, (2S-CIS)-
Common Name English
EZLOPITANT [USAN]
Common Name English
(2S,3S)-2-(Diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine
Systematic Name English
CJ-11974
Code English
(2S,3S)-2-(Diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-1-azabicyclo[2.2.2]octan-3-amine
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C267
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL515966
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
WIKIPEDIA
Ezlopitant
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID601318557
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
SMS_ID
300000034177
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
INN
7898
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
FDA UNII
3L098A8MPY
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
PUBCHEM
188927
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
NCI_THESAURUS
C97962
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
CAS
147116-64-1
Created by admin on Mon Mar 31 19:40:51 GMT 2025 , Edited by admin on Mon Mar 31 19:40:51 GMT 2025
PRIMARY
Related Record Type Details
Structure of EZLOPITANT DIHYDROCHLORIDE DIHYDRATE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
MAJOR
SUBSTANCE-P RECEPTOR
TARGET -> INHIBITOR
Ki
Structure of EZLOPITANT DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of CP-611781
METABOLITE -> PARENT
URINE
Structure of BENZENEMETHANOL, 3-(AMINOMETHYL)-4-METHOXY-.ALPHA.,.ALPHA.-DIMETHYL-
METABOLITE -> PARENT
URINE
Structure of 3-((((2S,3S)-2-(DIPHENYLMETHYL)-1-AZABICYCLO(2.2.2)OCT-3-YL)AMINO)METHYL)-4-HYDROXY-.ALPHA.,.ALPHA.-DIMETHYLBENZENEMETHANOL
METABOLITE -> PARENT
PLASMA
Structure of 3-((((2S,3S)-2-(DIPHENYLMETHYL)-1-AZABICYCLO(2.2.2)OCT-3-YL)AMINO)METHYL)-4-HYDROXY-.ALPHA.,.ALPHA.-DIMETHYLBENZENEMETHANOL
METABOLITE -> PARENT
URINE
Structure of CJ-12764
METABOLITE -> PARENT
URINE
Structure of BENZENEMETHANOL, 3-(AMINOMETHYL)-4-HYDROXY-.ALPHA.,.ALPHA.-DIMETHYL-
METABOLITE -> PARENT
URINE
Structure of 3-((((2S,3S)-2-(DIPHENYLMETHYL)-1-AZABICYCLO(2.2.2)OCT-3-YL)AMINO)METHYL)-4-METHOXY-.ALPHA.-METHYLBENZENEACETIC ACID
METABOLITE -> PARENT
FECAL
Structure of CJ-12764
METABOLITE ACTIVE -> PARENT
URINE
Structure of CJ-12764
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of 2-(3-(AMINOMETHYL)-4-HYDROXYPHENYL)-1,2-PROPANEDIOL
METABOLITE -> PARENT
URINE
Structure of 2-(3-((((2S,3S)-2-(DIPHENYLMETHYL)-1-AZABICYCLO(2.2.2)OCT-3-YL)AMINO)METHYL)-4-HYDROXYPHENYL)-1,2-PROPANEDIOL
METABOLITE -> PARENT
FECAL; URINE
Structure of CP-611781
METABOLITE -> PARENT
FECAL
Structure of CP-611781
METABOLITE -> PARENT
PLASMA
Structure of CJ-12458
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of 3-((((2S,3S)-2-(DIPHENYLMETHYL)-1-AZABICYCLO(2.2.2)OCT-3-YL)AMINO)METHYL)-4-METHOXY-.ALPHA.-METHYLBENZENEACETIC ACID
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of EZLOPITANT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966